Techno Medica (6678) Q4 2025 earnings summary

Executive summary

• Revenue decreased by 3.7% year-over-year to ¥9,905 million due to delayed large domestic projects, despite overseas sales ratio rising to 13.8% of total revenue, up 4.5 points year-over-year.

• Operating profit dropped 29.3% year-over-year to ¥1,300 million, and net profit fell 25.5% to ¥1,004 million, impacted by higher R&D and personnel costs.

• Cash and cash equivalents at year-end increased by ¥475 million to ¥9,061 million.

Financial highlights

• Gross profit was ¥4,928 million, down 4.3% year-over-year.

• Operating margin declined to 13.1% from 17.9% the previous year.

• Net assets rose to ¥14,389 million, with an equity ratio of 80.2%.

• EPS was ¥145.08, down from ¥172.95 year-over-year.

Outlook and guidance

• For the fiscal year ending March 2026, revenue is forecast to rise 7.0% to ¥10,600 million, with operating profit expected to increase 13.8% to ¥1,480 million and net profit to ¥1,100 million.

• Management expects steady order intake for delayed projects but anticipates higher SG&A costs.